How The US FDA Finds Pre-Approval Inspection Alternatives During COVID-19 Pandemic
Officials explain how remote record reviews, site transfers and other factors can green-light approvals of drugs and biologics.
You may also be interested in...
As Pandemic Delays Reduce PDUFA Revenues, US FDA Slows Fee-Related Spending
Agency cites “unexpected and large drop in collections” in slashing user-fee-setting contract.
It Was Inevitable: FDA Inspection Delay Postpones BMS’s Liso-Cel Approval
Bristol Myers Squibb confirmed that approval for lisocabtagene maraleucel (liso-cel) will be delayed by the US FDA’s COVID-19-related restrictions on travel for manufacturing facility inspectors.